Targeting CD19-CD22 Aids Younger Patients with ALL.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2020-060
Abstract: In a phase I trial of chimeric antigen receptor T cells targeting CD19 and CD22 in younger patients with relapsed or refractory B-cell acute lymphoblastic leukemia, toxicity was manageable, and five of 12 patients had… read more here.
Keywords: cd19 cd22; younger patients; aids younger; cd22 aids ... See more keywords